Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetes
MedTech
Dexcom hit by FDA Class I recall for its CGM system app
Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app.
Ben Adams
Nov 5, 2025 8:45am
Novo ends all cell therapy R&D, lets go of staff
Oct 10, 2025 3:30pm
Barinthus enters reverse merger with metabolic disease biotech
Sep 30, 2025 10:39am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
Glooko buys Monarch’s EndoTool to enter in-patient diabetes care
Sep 23, 2025 7:30am
Dexcom CEO goes on leave while Insulet taps new CFO
Sep 17, 2025 12:15pm
